前列腺切除术后磁共振引导自适应挽救放疗:前瞻性单中心队列的早期毒性与生化结局
中位随访20.8个月,急性GU毒性47%(≥2级8%),12个月GU毒性25例(≥2级10%),GI毒性急性和12个月均为12%;SIB亚组分析未见毒性显著增加。
要点
- MRgART用于前列腺切除术后挽救放疗可行,早期医生报告毒性良好。
- 3个月急性GU毒性47%(≥2级8%),12个月GU毒性25例(≥2级10%)。
- SIB亚组探索性分析未观察到早期或晚期毒性显著增加。
核心结论
- 前列腺切除术后MRgART联合或不联合PSMA-PET/MRI引导SIB在该前瞻性单中心队列中可行,并与良好的早期医生报告毒性相关。
- 探索性分析中SIB与早期或晚期毒性显著增加无关。
研究设计与样本
- 患者接受前列腺床±盆腔淋巴结MRgART,采用每日Adapt-to-Shape(ATS)工作流程。
- 在基线、治疗后3、6、12个月及最近一次临床随访时记录PSA和医生报告的GI、GU毒性。
主要发现
- 处方剂量包括52.5 Gy/20次、55 Gy/20次、64 Gy/32次、66 Gy/33次、68 Gy/34次或70 Gy/35次。
- 24例患者基于PSMA-PET和/或MRI发现接受同步整合推量(SIB,额外4.0-12.5 Gy)。
- 中位随访20.8个月(95%CI 17.8-34.1个月)。
- 3个月时47%发生急性GU毒性(39%为1级;8%为≥2级);12个月时25例报告GU毒性(40%为1级;10%为≥2级)。
- GI毒性急性期为12%,12个月时为12%;排除20例接受ADT的患者后,治疗后3个月PSA中位下降95.2%。
关键数值与推荐
- 急性GU毒性:3个月时47%(39%为1级;8%为≥2级)。
- 12个月GU毒性:25例报告(40%为1级;10%为≥2级)。
- GI毒性:急性期12%,12个月时12%。
- 排除20例接受ADT的患者后,3个月PSA中位下降95.2%。
- SIB亚组探索性分析:接受与未接受SIB的患者间未观察到统计学显著的毒性差异。
临床怎么用
- 对于根治性前列腺切除术后生化复发和/或影像学局部或淋巴结复发的患者,MRgART联合或不联合PSMA-PET/MRI引导SIB是可行的挽救放疗选择。
- 治疗期间及治疗后12个月内应关注GU和GI毒性,尤其是≥2级GU毒性。
- SIB的应用需结合PSMA-PET和/或MRI发现,并在探索性分析背景下评估其毒性风险。
局限性
- 需更长期随访、报告、患者报告结局和更大规模比较研究以确认毒性结局的持久性和定义长期生化控制。
- SIB与毒性的比较为探索性亚组分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Magnetic resonance-guided adaptive radiotherapy (MRgART) may support daily anatomical adaptation in salvage post-prostatectomy radiotherapy (sPPRT). This prospective single-center cohort reports early clinician-assessed toxicities and biochemical outcomes following post-prostatectomy MRgART. METHODS: Patients ≥6-months post-radical prostatectomy with positive margins, biochemical recurrence, and/or PSMA-PET/MRI-detected local or nodal recurrence were prospectively recruited to undergo MRgART to the prostate bed +/- pelvic lymph node irradiation. Patients were treated using a daily Adapt-to-Shape (ATS) workflow. PSA levels and clinician-reported gastrointestinal (GI) and genitourinary (GU) toxicities were recorded at baseline, 3, 6, and 12 months post-treatment and at most recent clinical follow-up. RESULTS: Fifty-one patients underwent salvage post-prostatectomy MRgART. Prescriptions included 52.5 Gy/20 fractions, 55 Gy/20 fractions, 64 Gy/32 fractions, 66 Gy/33 fractions, 68 Gy/34 fractions, or 70 Gy/35 fractions. A simultaneous integrated boost (SIB - additional 4.0-12.5 Gy) was delivered in 24 patients based on PSMA-PET and/or MRI findings. Median follow-up was 20.8 months (95% CI 17.8-34.1 months). At 3 months, 47% developed acute GU toxicity (39% grade 1; 8% grade ≥2). At 12 months, 25 patients reported GU toxicity (40% grade 1; 10% grade ≥2). GI toxicities were 12% acutely and 12% at 12 months. In exploratory subgroup analysis, no statistically significant toxicity difference was observed between patients receiving SIB and those not receiving SIB. Excluding 20 patients receiving ADT, PSA measurements demonstrated a median 95.2% reduction at 3 months post-treatment. CONCLUSIONS: Post-prostatectomy MRgART, with or without PSMA-PET/MRI-guided SIB, was feasible in this prospective single-center cohort and was associated with favourable early clinician-reported toxicity. SIB was not associated with a significant increase in early or late toxicity in exploratory analysis. Longer follow-up, reporting, patient-reported outcomes, and larger comparative studies are required to confirm durability of toxicity outcomes and define longer-term biochemical control.
引用
- Martin S, Byrne HL, Sim HW, et al. Post-prostatectomy magnetic resonance-guided adaptive salvage radiotherapy: early toxicity and biochemical outcomes from a prospective single center cohort. Clin Transl Radiat Oncol. 2026. PMID: 42724743. doi:10.1016/j.ctro.2026.101272
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。